Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed or Refractory CD10-Negative Diffuse Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements (HGBCL-DH-BCL2)

NCT06649812 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06649812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06649812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed or Refractory CD10-Negative Diffuse Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements (HGBCL-DH-BCL2)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Recruiting
Start date
October 7, 2025
Completion date
September 1, 2028
Enrollment
120 (estimated)
Sites
114

Conditions

As the registry lists them; a condition with its own page is linked.

high grade b-cell lymphoma with myc and bcl6 rearrangements, recurrent diffuse large b-cell lymphoma, recurrent diffuse large b-cell lymphoma germinal center b-cell type, recurrent diffuse large b-cell lymphoma, not otherwise specified, recurrent high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, recurrent high grade b-cell lymphoma with myc, bcl2, and bcl6 rearrangements, recurrent high grade b-cell lymphoma, not otherwise specified, recurrent t-cell/histiocyte-rich large b-cell lymphoma, refractory diffuse large b-cell lymphoma, refractory diffuse large b-cell lymphoma germinal center b-cell type, refractory diffuse large b-cell lymphoma, not otherwise specified, refractory high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, refractory high grade b-cell lymphoma with myc, bcl2, and bcl6 rearrangements, refractory high grade b-cell lymphoma, not otherwise specified, refractory t-cell/histiocyte-rich large b-cell lymphoma